M3935

Meloxicam sodium salt hydrate

≥98% (HPLC), anti-inflammatory agent, powder

• Synonyme(s) : 4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide sodium hydrate, Metacam sodium salt hydrate, Mobec sodium salt hydrate, UH-AC 62XX sodium salt hydrate
• Formule empirique (notation de Hill) : C₁₄H₁₂N₃NaO₄S₂ · xH₂O
• Numéro CAS: 71125-39-8
• Poids moléculaire : 373.38 (anhydrous basis)
• UNSPSC Code: 51111800
• PubChem Substance ID: 24278802
• NACRES: NA.77
• MDL number: MFCD11046047
• Assay: ≥98% (HPLC)
• Form: powder

Propriétés

• Nom du produit: Meloxicam sodium salt hydrate, ≥98% (HPLC)
• Quality Segment: 200
• assay: ≥98% (HPLC)
• form: powder
• color: light yellow to dark yellow
• solubility: DMSO: 5 mg/mL, clear
• originator: Boehringer Ingelheim
• storage temp.: room temp
• SMILES string: O.[Na+].CN1C(C(=O)Nc2ncc(C)s2)=C([O-])c3ccccc3S1(=O)=O
• InChI: 1S/C14H13N3O4S2.Na.H2O/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10(9)23(20,21)17(11)2;;/h3-7,18H,1-2H3,(H,15,16,19);;1H2/q;+1;/p-1
• InChI key: IZBZAOZGNNQKPJ-UHFFFAOYSA-M
• Gene Information: human ... PTGS2(5743)

Description

Application

Meloxicam sodium salt hydrate has been used:

• as a cyclooxygenase-2 (COX-2) inhibitor in solid Ehrlich tumor
• as an alternative to diclofenac nonsteroidal anti-inflammatory drugs (NSAID) to treat vultures
• as a reference standard in liquid chromatography electrospray ionisation mass spectrometry (LC-ESI/MS)
• to test its effect on prostaglandin (PGE2) production in lipopolysaccharide (LPS)-induced COX-2 protein expression in RAW246.7 cells

Biochem/physiol Actions

Meloxicam, a member of the oxicam family, is a non-steroidal anti-inflammatory drug (NSAID). It is synthesized from piroxicam with aryl and the pyridyl ring substitution. Meloxicam is a cyclooxygenase-2 (COX-2) inhibitor, it may be useful in treating inflammation and pain. Meloxicam has been shown to stop thymulin-induced increas in concentration of cytokines and Nerve growth factor (NGF) in the liver of rats. Meloxicam also suppresses tumor growth and may be capable of antagonizing cachexia in vitro. It promotes apoptosis in hepatocellular carcinoma.

Features and Benefits

This compound was developed by Boehringer Ingelheim. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Informations sur la sécurité

• pictograms: GHS06
• signalword: Danger
• hcodes: H301,H315,H319,H335
• pcodes: P301 + P310 + P330 - P302 + P352 - P305 + P351 + P338
• Hazard Classifications: Acute Tox. 3 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
• target_organs: Respiratory system
• Classe de stockage: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable